Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Triple Negative Breast Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm Metastasis 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Burkitt Lymphoma 1Breast Neoplasms 1

Interventions

Cyclophosphamide 6fludarabine phosphate 5Cytarabine 4Peripheral Blood Stem Cell Transplantation 3Methotrexate 3Doxorubicin 3venetoclax 2navitoclax 2merphos 2fludarabine 2Whole-Body Irradiation 2Vincristine 2Pentetic Acid 2Mycophenolic Acid 2Filgrastim 2Etoposide 2Daunorubicin 2Biopsy 2Asparaginase 2sargramostim 1romidepsin 1prednylidene 1pegaspargase 1nelarabine 1lentiviral minigene vaccine of COVID-19 coronavirus 1hydrocortisone hemisuccinate 1ethanolamine oleate 1duvelisib 1dexamethasone acetate 1dexamethasone 21-phosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × Liposomes × Clear all
NCT05320380 2023-09-01

A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat

Children's Oncology Group

Phase 1/2 Withdrawn
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡